• OFID 2018:5 (Suppl 1) • Poster Abstracts crisis of antibacterial resistance. Little is known about the genomic traits of the infant resistome, especially in areas with high endemic antibacterial resistance.
Microbiota and Associations with Treatment Outcome in Fecal Microbiota
Background. Fecal microbiota transplantation (FMT) can be an effective treatment of recurrent Clostridium difficile infection (CDI), although non-responsiveness to treatment remains poorly understood. Here we examine the bacterial composition of stool from FMT recipients using culture-independent methods to identify associations between bacterial community structure, route of FMT administration (colonoscopy or freeze-dried encapsulated FMT (capsules)), treatment outcome and donor. We hypothesized that multiple community structures could be associated with and may better define treatment outcome.
Methods. We tested this hypothesis by analyzing bacterial composition profiles and their relationship with treatment route, outcome and donor using bioinformatics and multivariate statistics on 16S rRNA gene sequences (16S) from 21 individuals (seven male, 14 female, median 68 years) with recurrent CDI prior to and after FMT. Successful endpoint was defined as no relapse of C. difficile associated diarrhea during 12 weeks post-FMT. There were 17 successes (four colonoscopy, 13 capsules) and four failures (all capsules). Analyses of 16S profiles included permutational analysis of variance (PERMANOVA) and linear regression models applied to bacterial abundances and diversity (as responses).
Results. Significant differences were determined between pre-and post-FMT successes and failures (P < 1e −4 , R 2 = 0.24). No differences were seen between route (P = 0.15) or donor (P = 0.20). Profiles of failed FMT recipients were more similar to pre-FMT profiles by multidimensional scaling. Analyses of changes in abundance of pre-FMT profiles vs. outcome, controlled for age and sex, identified significant (P < 0.01) differences across 19 of the 25 most abundant taxa. Of the five most abundant taxa, Enterobacteriaceae and Esherichia-Shigella decreased significantly in successful outcomes, while Faecalibacterium, Blautia, and Bacteroides increased. However, variation in individual composition was also significant suggesting that multiple profiles represent successful outcomes.
Conclusion. Increases in microbiota diversity are generally achieved in successful FMT regardless of administration route, although more than one bacterial composition profile can be identified.
Disclosures. All authors: No reported disclosures. Background. Staphylococcus aureus is the most common pathogen causing skin and soft-tissue infection and poses a particular problem to patients with atopic dermatitis who have increased colonization and infection rates. S. aureus is a versatile pathogen that adapts to the relatively hypoxic environment of the skin, although the underlying mechanisms of adaptation remain unclear. We hypothesized that adaptation to the skin is largely driven by metabolic interactions between S. aureus and keratinocytes.
Metabolic Interactions Drive Staphylococcus aureus
Methods. We characterized 10 clinical S. aureus isolates obtained from individual patients with atopic dermatitis using whole genome sequencing and qRT-PCR to evaluate their genotypic and phenotypic properties. The metabolic and inflammatory responses of keratinocytes to S. aureus infection were assessed in vitro in primary human keratinocytes and in vivo in a murine cutaneous abscess model.
Results. Host-adapted S. aureus isolates from atopic dermatitis patients are phylogenetically diverse and are associated with varying severity of disease. They stimulate glycolysis and stabilize HIF1α in keratinocytes, and produce a similar infectious phenotype to WT USA300 LAC in a murine cutaneous abscess model. Numerous metabolic nonsynonymous mutations in genes encoding glycolytic and TCA cycle enzymes were identified in these strains. Increased expression of fumC, that encodes fumarase which hydrates fumarate to malate in the TCA cycle, was observed in the clinical isolates compared with WT LAC. Based on this finding and recent literature demonstrating that fumarate accumulation in immune cells is vital for trained immunity and that it inhibits glycolysis via GAPDH inactivation, we hypothesized that hostadapted S. aureus strains upregulate fumarase in response to increased fumarate levels in the skin. Keratinocytes infected with our clinical strains secrete increased fumarate compared with uninfected keratinocytes.
Conclusion. S. aureus strains from atopic dermatitis skin represent a diverse population that are unified in their ability to adapt via metabolic interactions with keratinocytes. They adapt to increased fumarate levels in the skin by upregulating fumarase which likely represents a feedback inhibitory response to increased glycolysis in keratinocytes.
Disclosures. Background. Due to ethical and budgetary concerns associated with the use of vertebrate animals in research, interest in alternative models has increased over the past several decades. In the present study, we developed a Candida albicans quantitative infection model in Caenorhabditis elegans, a nonparasitic invertebrate nematode, to test the antifungal effects of liposomal amphotericin B (L-AmB).
Methods. To establish a lethal C. albicans infection, larval Stage 4 worms [n = 30/ group (gp)] were fed various doses of yeast (2.5 × 10 2 -2.5 × 10 5 cells/gp) for 4 hours at 20°C or 30°C. The infection was evaluated by monitoring worms for mortality and determining fungal burden in worm homogenates by plating for colony forming units every 24 hours for 4 days post-challenge. To examine the worm's ability to ingest L-AmB and to determine drug toxicity, uninfected worms were fed L-AmB (6.3-25 μg/ gp) for 4 hours at 30°C, and drug toxicity evaluated by survival with drug concentrations determined by bioassay of worm homogenates. The lack of toxicity allowed us to evaluate L-AmB activity in worms challenged for 4 hours at 30°C with 2.5 × 10 5 yeast cells/gp and then treated with L-AmB (0.5-25 ug/gp) for 4 hours at 30°C, with survival rate and fungal burden to assess L-AmB treatment.
Results. Calbicans infection was established in worms challenged with all yeast doses, with optimum infection observed with 2.5 × 10 5 yeast cells/gp at 30°C (13% survival in-infected worms vs. 87% in uninfected worms). We observed that uninfected worms could take up L-AmB at doses of 6.3-25 μg/gp and yet was not toxic for the worms (93-95% survival). In worms exposed to yeast and treated with L-AmB, complete clearance of infection was achieved with the higher doses (6.3-25 μg/gp), while lower doses (1.6-3.1 μg/gp) significantly reduced the fungal burden (P ≤ 0.05). Infected worms, not treated with L-AmB had only 10% survival, while L-AmB improved survival in a dose-dependent manner giving 40% survival for 0.5 μg L-AmBi/gp and 100% survival for doses of 6.3 μg/gp and higher.
Conclusion. By using fungal burden as a readout of efficacy, along with survival, we have established a quantitative, reproducible, flexible method for examining the activity of L-AmB in C. elegans which could be expanded for use in evaluating other antifungal drugs and different pathogenic fungi.
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